Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:02:25.017Z.
Consensus retrieved: 2026-10-06T12:06:41.246Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:02:25.017Z.
Quote observation: 2026-10-06T17:58:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 451a64ce4da380df6ab4c5027584c6fd3c25ecc0cb3c19eab7daced69cd0f5b9
FORWARD PE RATIO
N/A
Grace Therapeutics, Inc.
Market Cap
$34.42M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $34.42M | N/A |
| Elutia Inc (ELUT)vs › | $34.48M | N/A |
| Accuray Incorporated (ARAY)vs › | $34.21M | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.06M | N/A |
| HeartBeam, Inc. (BEAT)vs › | $33.59M | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.26M | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $35.69M | 11.94 |
| DocGo Inc. (DCGO)vs › | $35.81M | N/A |
| Scilex Holding Company (SCLX)vs › | $32.82M | N/A |
| Rockwell Medical, Inc. (RMTI)vs › | $32.68M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-03-31
Consensus estimates for this stock are reported in USD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
